DrugPatentWatch Database Preview
Try a free trialSee Plans and Pricing
« Back to Dashboard
Summary for Patent: 9,226,892
|Title:||pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same|
|Abstract:||Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia.|
|Inventor(s):||Marathi; Upendra K. (Houston, TX), Childress; Susann Edler (Houston, TX), Gammill; Shaun L. (Houston, TX), Strozier; Robert W. (Houston, TX)|
|Assignee:||PLX PHARMA INC. (Houston, TX)|
1. A method of targeting release of a non-steroidal anti-inflammatory drug (NSAID) to the small intestine of a subject, comprising: orally administering to the subject an ingestible
composition consisting of a non-aqueous solid-in-oil suspension of an effective amount of the solid NSAID in a carrier, wherein the carrier comprises at least one free fatty acid having at least 8 carbon atoms in an amount greater than about 10 wt. %,
and wherein the carrier comprises from about 0.0001 wt. % to about 5 wt. % of zwitterionic phospholipids, whereby the composition displays less gastrointestinal toxicity than the NSAID alone.
2. The method of claim 1, wherein at least one free fatty acid is present in the carrier at a level greater than 14 wt. % of the carrier.
3. The method of claim 2, wherein the carrier further comprises triglycerides.
4. The method of claim 1, wherein the carrier releases a minimal amount of the NSAID at pH<3 as compared to at pH>3.
5. The method of claim 4, wherein less than 20% of the NSAID is released from the carrier at pH<3 and greater than 50% of the NSAID is released from the carrier at pH>3.
6. The method of claim 1, wherein the NSAID is selected from the group consisting of ibuprofen, piroxicam, salicylate, aspirin, naproxen, indomethacin, diclofenac, mefenamic acid, COX2 inhibitors and any mixture thereof.
7. The method of claim 6, wherein the NSAID is selected from the group consisting of ibuprofen, aspirin, naproxen, indomethacin, mefenamic acid, and any mixture thereof.
8. The method of claim 1, wherein the amount of zwitterionic phospholipids is selected from the group consisting of about 0 wt. %, about 0.5 wt. %, about 1 wt. %, about 2 wt. %, about 2.5 wt. %, about 5 wt. %, less than 2.5 wt. %, and less than 5 wt. %.
9. The method of claim 1, wherein the amount of zwitterionic phospholipids is from about 0.5 wt. % up to about 2.5 wt. %.
10. The method of claim 1, wherein the amount of zwitterionic phospholipids is selected from the group consisting of about 0.5 wt. %, about 1 wt. %, about 2 wt. %, about 2.5 wt. %, and about 5 wt. %.
Make Better Decisions: Try a trial or see plans & pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.